Healthcare
Theralink Technologies, Inc.(THER)
Live Price
Offline$0.0001
+0.00% today
1Y Change
+0.00%
Window
Jun 23, 2025 โ Jun 12, 2026
- Market Cap
- โ
- Revenue Growth
- +6.8%
- EPS Growth
- -127.3%
- Dividend Yield
- 0.0%
Coverage: 245 bars ยท Jun 23, 2025 โ Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Theralink Technologies, Inc. (THER) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 23, 2025 โ Jun 12, 2026). Baseline metrics include revenue growth of +6.8%, EPS growth of -127.3%, a dividend yield of 0.0%. What stands out right now is revenue +6.8%, EPS -127.3%, free cash flow -7.6% with operating margin -1479.8% and ROIC 48.9%. Valuation is more restrained than many high-expectation growth names at price/sales 1.0. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines THER price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Near sector median
+6.8% vs +7.6% peer median
Operating Margin
Below sector median
-1479.8% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2025 was reported on Jan 3, 2025, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at +6.8% and EPS is at -127.3%, with operating margin around -1479.8%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2025 Jan 3, 2025 | โ | +0.0% | +0.0% | +0.0% |
2024 Nov 13, 2024 | โ | +0.0% | +0.0% | +0.0% |
2024 Aug 29, 2024 | โ | +0.0% | +0.0% | +0.0% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
THER
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
THER Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for THER and SPY.
Company Overview
Theralink Technologies, Inc.
Other OTC
Theralink Technologies, Inc., a commercial-stage precision medicine and molecular data-generating company, engages in the development and commercialization of novel cancer immunotherapy products. The company through its patented phosphoprotein and protein biomarker platform, and laboratory developed test technology targets multiple areas of oncology and drug development. It provides precision oncology data through its Theralink Reverse Phase Protein Array assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders and non-responders to FDA-approved and investigational drug treatments. The company's data-generating assays provide actionable information for physicians, patients, and biopharmaceutical companies in the area of oncology. Theralink Technologies, Inc. was formerly known as OncBioMune Pharmaceuticals, Inc. and changed its name to Theralink Technologies, Inc. in September 2020. The company is headquartered in Golden, Colorado.
- Leadership
- Michael I. Ruxin
- IPO Date
- Apr 1, 2010
- Employees
- 16
- Street Address
- 15000 West 6th Avenue
- Mailing
- Golden, CO, 80401
- Region
- Golden, CO, US
- Reporting Currency
- USD
- Investor Line
- 720 420 0074
- Last Updated
- May 5, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 1.0
- Price/Book
- โ
Growth
- Revenue
- +6.8%
- EPS
- -127.3%
- Free Cash Flow
- -7.6%
Profitability
- Gross Margin
- 79.2%
- Operating Margin
- -1479.8%
- Net Margin
- -5093.6%
- ROE
- 147.5%
- ROIC
- 48.9%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.03
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.